Daily Alpha · X
· Midday Alpha · by Buzzberg Research
X mixed fresh dip-buying with harder supply-chain evidence: Asian stabilization steps, a possible Rubin/HBM4 delay, and disclosed adds in Bloom Energy and Hims.
Themes on this desk
Memory and HBM
Jukan links KYEC's cut to a Rubin/HBM4 delay; BofA reports investors turned more bearish on memory, citing few new catalysts.
Asia stabilization
An @aleabitoreddit post tracks Taiwan short-selling limits, Korea margin relief and China liquidity support for AI-linked equities.
Ticker heat
?
Top voices by smart followers and alpha score
Market Radar →Jukan links KYEC's Q4 guidance cut to an Nvidia Rubin delay from HBM4 yield issues
Jukan says Taiwan's KYEC lowered Q4 guidance because of delays affecting a major GPU, believed to be Nvidia's Rubin, caused by HBM4 yield problems at a memory supplier.
Taiwan’s KYEC lowered its Q4 guidance due to delays affecting a major GPU, believed to be NVIDIA’s Rubin, caused by
A Rubin timing slip hits HBM4 and test suppliers before it hits AI demand, a cleaner negative signal than index volatility.
Watch Nvidia's Rubin schedule, HBM4 qualification at SK Hynix, Samsung and Micron, and KYEC orders.
Source →Taiwan, Korea and China move to curb forced selling with short-selling limits and liquidity support
A post from @aleabitoreddit says Taiwan will cut borrowed-share short selling from 30% to 3% of order volume from Nov. 9, raise margin short collateral from 90% to 130% and authorize a $15.3B stabilization fund; Korea will waive 140% margin-loan collateral for three months and China introduced a $15B liquidity-swap operation.
In response to the recent market volatility across $TSM to $SKHY to Innolight:
The measures aim to reduce forced selling in markets tied to the AI trade, with Nov. 9 as the effective date.
Watch Whether forced selling eases after Nov. 9 and whether the announced support holds indices.
Source →ren_stocks bought a large amount of Bloom Energy, calling power the real AI constraint
The investor disclosed a large Bloom Energy purchase and argued power is the real constraint, especially under Democrats, linking the position to data-center power scarcity.
I bought a LARGE amount of $BE I love where this company is headed.
A fresh, disclosed buy and a concrete power-scarcity expression rather than another AI-compute beta trade.
Watch New Bloom fuel-cell orders or hyperscaler power contracts.
Source →TheValueist says LLMs are commoditizing and value sits with AI picks-and-shovels suppliers
TheValueist argues the LLMs themselves are a commodity and most value will accrue to picks-and-shovels suppliers, pointing to infrastructure names regaining ground while LLM vendors fade; he says the shift will play out over months, not one day.
$NVDA $MU $SNDK $LITE $ANT As I have said countless times, I believe the majority of value captured in the
It frames the selloff as rotation within AI, not an exit from AI capex.
Watch Relative performance of Nvidia, memory and optics versus Anthropic/LLM vendors, plus options expiry and the Anthropic IPO.
Source →Jonah Lupton adds Hims after Lilly deal, calling Retatrutide access more important than Zepbound
Lupton says he just bought more HIMS because the Lilly agreement sets up access to Retatrutide, which he views as 10x more important than Zepbound and Foundayo.
@himshouse Here’s my read through and why we just bought more $HIMS … This sets the stage for access to
The incremental bull case is a future obesity-drug distribution slot, not current GLP-1 resale; that is a thesis change investors can test.
Watch Hims subscription growth, Lilly's Retatrutide timeline and pricing/compounding conflict.
Source →